Home › Research › Brain tissue and pathology
Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls
Ryan T. Muir, Sophie K. Stukas, Jennifer G Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala et al.. Alzheimer s & Dementia, 2025-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta‐amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ 42/40 , phosphorylated‐tau (p‐tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls. METHODS Plasma Aβ 42/40 , p‐tau‐181, NfL, and GFAP were quantified using single molecule array (Simoa) and Aβ 42/40 was also independently quantified using immunoprecipitation liquid chromatography mass‐spectrometry (IPMS). RESULTS Forty‐five participants with CAA and 47 healthy controls had available plasma. Aβ 42/40 ratios were significantly lower in CAA than healthy controls. While p‐tau‐181 and NfL were elevated in CAA, GFAP was similar. A combination of Aβ 42/40 (Simoa), p‐tau‐181, and NfL resulted in an area under the curve of 0.90 (95% confidence interval: 0.80, 0.95). DISCUSSION Plasma Aβ 42/40 , p‐tau‐181, and NfL differ in those with CAA and together can discriminate CAA from healthy controls. Highlights Participants with CAA had reduced plasma Aβ 42/40 ratios compared to controls. Plasma p‐tau‐181 and NfL concentrations are elevated in CAA compared to controls. Plasma GFAP was similar in CAA and controls. Together, plasma Aβ 42/40 , p‐tau‐181, and NfL had excellent discriminability for CAA.
What this study adds
Evidence grade: Low
In 45 people with CAA and 47 healthy controls, a combination of plasma Aβ 42/40, p-tau-181 and NfL distinguished CAA from controls with an area under the curve of 0.90. This is a diagnostic finding only and does not address treating, curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Muir, R. T., Stukas, S. K., Cooper, J. G., Beaudin, A. E., McCreary, C. R., Gee, M., et al. (2025). Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70010
Vancouver
Muir RT, Stukas SK, Cooper JG, Beaudin AE, McCreary CR, Gee M, et al. Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70010. PMID: 40156276.
BibTeX
@article{muir2025-40156276,
author = {Muir, Ryan T. and Stukas, Sophie K. and Cooper, Jennifer G and Beaudin, Andrew E. and McCreary, Cheryl R. and Gee, Myrlene and Nelles, Krista and Nukala, Nikita and others},
title = {{Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70010},
pmid = {40156276},
url = {https://doi.org/10.1002/alz.70010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- RESULTS Forty‐five participants with CAA and 47 healthy controls had available plasma.
- Aβ 42/40 ratios were significantly lower in CAA than healthy controls.
- Highlights Participants with CAA had reduced plasma Aβ 42/40 ratios compared to controls.
- Plasma p‐tau‐181 and NfL concentrations are elevated in CAA compared to controls.
Why it matters
In 45 people with CAA and 47 healthy controls, a combination of plasma Aβ 42/40, p-tau-181 and NfL distinguished CAA from controls with an area under the curve of 0.90. This is a diagnostic finding only and does not address treating, curing or preventing Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 6.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Eric Edward Smith: h-index 127 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Toronto: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40156276) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Brain tissue and pathology from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.